Skip to main content

3 Result(s)

within Christoph Wanner Remove this filter Cardiology Remove this filter Internal Medicine Remove this filter

and
Your search also matched 1 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

Update zur diastolisch bedingten Herzinsuffizienz

Include preview-only content

  1. Article

    Open Access

    Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials

    Empagliflozin is a sodium-glucose co-transporter-2 inhibitor used to treat type 2 diabetes (T2D) to improve glycemic control, reduce risk of cardiovascular death in patients with T2D, and treat patients with s...

    Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler… in Advances in Therapy (2024)

    Download PDF (356 KB) View Article

  2. Article

    Open Access

    Guardians For Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 Diabetes

    Type 2 diabetes is one of the fastest-growing health emergencies of the twenty-first century, in part due to its association with cardiovascular and renal disease. Successful implementation of evidence-based g...

    Naresh Kanumilli, Javed Butler, Konstantinos Makrilakis, Lars Rydén… in Diabetes Therapy (2023)

    Download PDF (2223 KB) View Article

  3. Article

    Open Access

    Herzinsuffizienzprotektion bei Patienten mit Diabetes mellitus Typ 2 durch SGLT2-Inhibitoren – Evidenzlage und mögliche Mechanismen

    Hemmstoffe des renalen Natrium-Glukose-Kotransporters 2 („sodium glucose-linked transporter 2“; SGLT2i) scheinen außer der antidiabetischen auch eine kardioprotektive Wirkung zu besitzen; deren Mechanismus ist...

    Dr. med. Andreas J. Rieth, Christian W. Hamm, Christoph Wanner, Veselin Mitrovic… in Herz (2021)

    Download PDF (1955 KB) View Article